XAIR · Beyond Air, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Management believes these factors raise substantial doubt about the Company's ability to meet its obligations with cash on hand and concluded that the Company will require additional funding within one year from the date these financial statements are issued. Management is confident that the efforts to arrange financing, while not assured, will enable them to meet the Company's obligations.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jul 13, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jul 13, 2026.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XAIR
this stock
Beyond Air, Inc.
|
$3.06M | — | +107.3% | — | 7.6% |
|
ABT
Abbott Laboratories
|
$177.58B | -18.6% | +5.7% | 28.6 | 1.3% |
|
MDT
Medtronic plc
|
$116.35B | -5.3% | +8.4% | 22.4 | 0.9% |
|
SYK
Stryker Corp
|
$105.70B | -21.6% | +11.2% | 28.6 | 2.0% |
|
BSX
Boston Scientific Corp
|
$62.29B | -54.9% | +12.5% | 17.4 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jul 13, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XAIR | -10.9% | -53.8% | — | -19.4% | — |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -9.7% | -52.0% | — | -19.0% | — |